Insider Analysis from Sidley Austin LLP: The Coke/Huiyuan Veto and Its Implication for Life Sciences Companies in China
This article was originally published in PharmAsia News
Executive Summary
By William Fifield, Chen Yang, Katherine Wang and Adrian Emch, Sidley Austin LL